Brief: Sol-Gel Technologies Announces FDA Approval Of Twyneo®
July 27 (Reuters) - Sol Gel Technologies Ltd SLGL.O :
* SOL-GEL TECHNOLOGIES ANNOUNCES FDA APPROVAL OF TWYNEO®
* SOL GEL TECHNOLOGIES LTD - EXPECTS TO RECEIVE A REGULATORY
MILESTONE PAYMENT IN CONJUNCTION WITH APPROVAL
* SOL GEL TECHNOLOGIES LTD - RETAINS OPTION TO REGAIN U.S.
COMMERCIALIZATION RIGHTS FIVE YEARS FOLLOWING FIRST
COMMERCIALIZATION IN U.S.
Source text for Eikon: ID:nGNX2QPs6d
Further company coverage: SLGL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SOL-GEL TECHNOLOGIES
See all newsIsraeli dermatology firm Sol-Gel's Q2 revenue drops sharply on prior-year IP sale
SOL-GEL TECHNOLOGIES LTD. expected to post a loss of $2.57 a share - Earnings Preview
Sol-Gel Q1 revenue falls sharply on milestone payment impact
Brief: Sol-Gel Technologies Ltd. Q1 Revenue USD 100 Thousand
Brief: Sol-Gel Technologies Ltd. Announces Pricing Of Oversubscribed Underwritten Offering